Table 5 Details of individual ambulatory care expenditures for patients with T2DM and normal renal function and for non-diabetic controls in 2010 (€)
From: Impact of therapy escalation on ambulatory care costs among patients with type 2 diabetes in France
Consultations visits | Physio-therapist | Nursing care | Biological diagnostic tests | Radiology/medical imaging | Medical devices | Transportation | Invalidity | Pharmacy | Others | Total ambulatory care costs | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Monotherapy (mono): m (σ) | 256 (190) | 90 (339) | 144 (853) | 159 (175) | 113 (191) | 272 (861) | 88 (449) | 219 (1,451) | 1,156 (1,786) | 521 (1,528) | 3,017 (3,829) |
Double therapy (bi): m (σ) | 257 (156) | 88 (372) | 152(885) | 155 (158) | 107 (186) | 294 (728) | 98 (787) | 240 (1,730) | 1,411 (1,650) | 506 (1,679) | 3,308 (4,045) |
Cost ratio vs mono | 1.045 | 0.909 | 1.392 | 1.070 | 0.940 | 1.237 | 1.113 | 0.976 | 1.236 | 0.885 | 1.102 |
Triple therapy (tri): m (σ) | 252 (146) | 55(280) | 94 (646) | 149 (129) | 110 (188) | 272 (410) | 112 (707) | 308 (1,857) | 1,798 (1,509) | 460 (1,337) | 3,609(3,801) |
Cost ratio vs bi | 1.044 | 0.728 | 0.675 | 0.977 | 1.038 | 1.059 | 1.022 | 1.026 | 1.287 | 0.926 | 1.101 |
Insulin therapy: m (σ) | 329 (208) | 157 (499) | 1,586 (2761) | 198 (210) | 140 (221) | 1,216 (1,697) | 264 (1,064) | 444 (2,025) | 2,646 (2,124) | 420 (1,093) | 7,398(5,487) |
Cost ratio vs tri | 1.200 | 2.509 | 18.420 | 1.189 | 1.178 | 3.931 | 2.480 | 2.929 | 1.331 | 1.228 | 1.942 |
Non diabetic patients | 175 (184) | 81 (324) | 101 (977) | 93 (176) | 95 (170) | 160 (805) | 85 (582) | 136 (1,131) | 702 (2,142) | 538 (1,799) | 2,166 (4,102) |
Additional costs vs non diabetic patients: € (increase rate in %) | |||||||||||
Monotherapy | 80 (46.3%) | 9 (11.1%) | 43 (42.6%) | 66 (71.0%) | 18 (18.9%) | 112 (70.0%) | 3 (3.5%) | 83 (61.0%) | 454 (64.7%) | −17 (-3.2%) | 852 (39.3%) |
Double therapy | 81 (46.9%) | 7 (8.6%) | 51 (50.5%) | 62 (66.7%) | 12 (12.6%) | 134 (83.8%) | 13 (15.3%) | 104 (76.5%) | 709 (101.0%) | −32 (-5.9%) | 1,142 (52.7%) |
Triple therapy | 77 (44.0%) | −26 (-32.1%) | −7 (-6.9%) | 56 (60.2%) | 15 (15.8%) | 112 (70.0%) | 27 (31.8%) | 172 (126.5%) | 1,096 (156.1%) | −78 (-14.5%) | 1,444 (66.7%) |
Insulin therapy | 154 (88.0%) | 76 (93.8%) | 1,485 (1,470.3%) | 105 (112.9%) | 45 (47.4%) | 1,056 (660.0%) | 179 (210.6%) | 308 (226.5%) | 1,944 (276.9%) | −118 (-21.9%) | 5,234 (241.7%) |